Literature DB >> 27493616

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer.

Johannes Ettl1.   

Abstract

Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed.

Entities:  

Keywords:  Advanced breast cancer; CDK4/6; Cell cycle; Endocrine therapy; Palbociclib

Year:  2016        PMID： 27493616      PMCID： PMC4960350          DOI： 10.1159/000447417

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


  8 in total

1.  ABC3 Consensus: Assessment by a German Group of Experts.

Authors:  Christoph Thomssen; Doris Augustin; Johannes Ettl; Renate Haidinger; Hans-Joachim Lück; Diana Lüftner; Frederik Marmé; Norbert Marschner; Lothar Müller; Friedrich Overkamp; Eugen Ruckhäberle; Marc Thill; Michael Untch; Rachel Wuerstlein; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2016-01-29       Impact factor: 2.860

2.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Authors:  Nicholas C Turner; Jungsil Ro; Fabrice André; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Sibylle Loibl; Cynthia Huang Bartlett; Ke Zhang; Carla Giorgetti; Sophia Randolph; Maria Koehler; Massimo Cristofanilli
Journal:  N Engl J Med       Date:  2015-06-01       Impact factor: 91.245

3.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Authors:  Richard S Finn; John P Crown; Istvan Lang; Katalin Boer; Igor M Bondarenko; Sergey O Kulyk; Johannes Ettl; Ravindranath Patel; Tamas Pinter; Marcus Schmidt; Yaroslav Shparyk; Anu R Thummala; Nataliya L Voytko; Camilla Fowst; Xin Huang; Sindy T Kim; Sophia Randolph; Dennis J Slamon
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

Review 4.  Cell cycle control in breast cancer cells.

Authors:  C Elizabeth Caldon; Roger J Daly; Robert L Sutherland; Elizabeth A Musgrove
Journal:  J Cell Biochem       Date:  2006-02-01       Impact factor: 4.429

5.  Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.

Authors:  Keith T Flaherty; Patricia M Lorusso; Angela Demichele; Vandana G Abramson; Rachel Courtney; Sophia S Randolph; M Naveed Shaik; Keith D Wilner; Peter J O'Dwyer; Gary K Schwartz
Journal:  Clin Cancer Res       Date:  2011-11-16       Impact factor: 12.531

6.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Authors:  Richard S Finn; Judy Dering; Dylan Conklin; Ondrej Kalous; David J Cohen; Amrita J Desai; Charles Ginther; Mohammad Atefi; Isan Chen; Camilla Fowst; Gerret Los; Dennis J Slamon
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

7.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Authors:  David W Fry; Patricia J Harvey; Paul R Keller; William L Elliott; Maryanne Meade; Erin Trachet; Mudher Albassam; XianXian Zheng; Wilbur R Leopold; Nancy K Pryer; Peter L Toogood
Journal:  Mol Cancer Ther       Date:  2004-11       Impact factor: 6.261

8.  Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.

Authors:  N Harbeck; S Iyer; N Turner; M Cristofanilli; J Ro; F André; S Loi; S Verma; H Iwata; H Bhattacharyya; K Puyana Theall; C H Bartlett; S Loibl
Journal:  Ann Oncol       Date:  2016-03-30       Impact factor: 32.976
  8 in total
  4 in total

1.  The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment.

Authors:  Isabell Witzel; Volkmar Müller
Journal:  Breast Care (Basel)       Date:  2016-06-22       Impact factor: 2.860

Review 2.  Glioma: experimental models and reality.

Authors:  Krissie Lenting; Roel Verhaak; Mark Ter Laan; Pieter Wesseling; William Leenders
Journal:  Acta Neuropathol       Date:  2017-01-10       Impact factor: 17.088

3.  Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension.

Authors:  Astrid Weiss; Moritz Christian Neubauer; Dinesh Yerabolu; Baktybek Kojonazarov; Beate Christiane Schlueter; Lavinia Neubert; Danny Jonigk; Nelli Baal; Clemens Ruppert; Peter Dorfmuller; Soni Savai Pullamsetti; Norbert Weissmann; Hossein-Ardeschir Ghofrani; Friedrich Grimminger; Werner Seeger; Ralph Theo Schermuly
Journal:  Nat Commun       Date:  2019-05-17       Impact factor: 14.919

Review 4.  A Comprehensive Review on Schisandrin B and Its Biological Properties.

Authors:  M I Nasser; Shuoji Zhu; Chen Chen; Mingyi Zhao; Huanlei Huang; Ping Zhu
Journal:  Oxid Med Cell Longev       Date:  2020-03-14       Impact factor: 6.543
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.